Harmony Biosciences Holdings, Inc. (HRMY) Stock Forecast and Price Target (2026)

The average target of $47.64 sits above the $39.58 price, +20.4%. The median is $50.00, and where the two differ the median is the steadier read, because one unusually high or low target cannot drag it.

The published targets span $30.00 to $70.00. That gap is 84% of the average target, which counts as wide disagreement. A spread that wide is the most informative number on this page: analysts who all follow the company closely cannot agree within a factor that large, which means the outcome genuinely depends on assumptions nobody can settle yet.

The useful move is to read the high target as one bull scenario and the low target as one bear scenario, then ask which set of assumptions you find more plausible. Both cases are worked through on the HRMY is it a buy page.

In the last six months there have been 5 raises and 0 cuts among these actions. The direction of revisions is often more telling than the level, because it shows which way informed opinion is moving.

Of the analysts with a published rating, 7 say buy, 3 say hold, and 1 says sell, so 64% carry a buy. That buy share has risen over the last three months, so sentiment is drifting more positive.

Read the distribution rather than the label. Sell ratings are rare across the entire market for structural reasons, so a stock with no sell ratings is unremarkable, while even a handful of them is worth understanding.

• It is a 12-month model output. An analyst picks assumptions for revenue, margin, and a multiple, and the target falls out of the arithmetic. Change one assumption and the target moves a lot.
• The distribution is skewed. Sell-side coverage carries far more buy ratings than sell ratings across the whole market, so the average is not a balanced vote.
• Targets follow price as often as they lead it. Revisions frequently arrive after a move, not before, which is why a rising target is weak evidence on its own.
• Nobody is scored on it. There is no cost to a target that never gets close, so treat accuracy as unverified unless you check the firm's record yourself.

Not a published one. Analyst price targets run to about twelve months, occasionally two years, and the firms covering HRMY do not put out a 2030 number. Anything presenting one is extrapolating a growth rate rather than reporting research, and a figure produced that way tells you about the assumption chosen, not about the company.

On the figures we hold as of October 2026, HRMY trades at about 12.8 times trailing earnings and 5.9 times forward earnings. A forward multiple below the trailing one means the market expects earnings to grow, and the size of that gap is roughly how much growth is already in the price.

That is the more useful frame for a ten-year question. A share price is the market’s estimate of future cash flows discounted to today, so the multiple is already a statement about growth. The long-horizon question is whether Harmony Biosciences Holdings, Inc. can deliver what is priced in, and what would have to change for that to break. Both are answerable from the drivers and risks below. A number for 2030 is not.

In short: the drivers cited most often are WAKIX is still accelerating in year seven, The pitolisant franchise extension is the answer to 2030, BP-205 puts Harmony in the orexin race. The risk cited most often against it is one product carries the entire company, and its exclusivity has a date on it: WAKIX runs to March 2030 including the pediatric extension, and six of the seven ANDA filers (Lupin, Novugen, Novitium, Hikma, Annora and MSN) have already settled to license dates in 2030, which makes generic entry scheduled rather than hypothetical.

Both sides are worked through properly, with the high and low targets used as the bull and bear anchors, on the HRMY is it a buy page. This page deliberately stops at the numbers.